Sustained revenue growth
Revenue rose for three straight years through 2025 to KRW 105.2 billion. The bull case is that a larger revenue base could widen margins if profitability recovers. The operating margin, however, fell to -3.5% in 2025.
PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close
Revenue rose for three straight years through 2025, but operating losses have continued for three consecutive quarters from the first quarter of 2026 through the third quarter, making the monetization of Mezofy and the edoxaban generic the next checkpoint.
Revenue reached KRW 105.2 billion in 2025, up 6.2% year on year and rising for three straight years, but the company swung to an operating loss of KRW 3.69 billion that year.
The operating loss widened to KRW 4.96 billion in the third quarter of 2026, and the cumulative controlling-shareholder net loss for the last four quarters totals KRW 14 billion.
Mezofy received FDA marketing approval in April 2025, but its US prescription uptake and revenue contribution remain under verification.
The edoxaban generic launched on November 11, 2026 as the first generic of Lixiana, with a reimbursement price about 36% below the original.
After a 10-for-1 reverse stock split, the shares resumed trading on October 27, 2026, a step aimed at reducing the risk of administrative-issue designation.
CMG Pharmaceutical is a pharmaceutical affiliate of a biotech group, centered on prescription drugs (ETC) with over-the-counter products, health functional foods and research on improved new drugs. A 2023 outlook report put the sales mix at 70% prescription drugs, 2% OTC, 6% health functional foods and 22% other.
The company holds about 350 product items, with circulatory and neurological therapeutic areas accounting for the largest shares. Its core platform is the STARFILM oral dissolving film technology, which it applies to improved new drugs and is extending into oncology, ophthalmology and anti-aging.
The lead product Mezofy (formerly Depipzo) is an oral film-type schizophrenia treatment based on aripiprazole, and it received FDA marketing approval in April 2025. Reports say aripiprazole's use patent expired in 2022 and that no competing film-type product exists.
In November 2026 the company launched the edoxaban generic Edoxin, extending its cardiovascular portfolio. Its animal health unit was set up at the end of 2022 and it acquired an animal nutrition company in January 2023. Sales efforts focus on general hospitals and clinics.
Compared with large domestic pharma groups, its product mix is weighted toward generics, and its three small-molecule new drugs for lung cancer, osteoarthritis and hair loss remain early-stage, with its CNS and improved-drug businesses not yet a major profit contributor.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q3 | ₩30.4B | ₩1.2B | 4.0% |
| 2025Q4 | ₩31.5B | ₩1B | 3.3% |
| 2026Q1 | ₩25.5B | -₩2.9B | −11.5% |
| 2026Q2 | ₩28.3B | -₩3B | −10.4% |
| 2026Q3 | ₩22.8B | -₩5B | −21.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩82.2B | ₩3B | -₩400M | 3.6% | −0.2% | 15.3% |
| 2023 | ₩93.9B | ₩3B | ₩6.5B | 3.2% | 3.4% | 27.3% |
| 2024 | ₩99.1B | ₩1B | ₩2.7B | 1.0% | 1.4% | 60.1% |
| 2025 | ₩105.2B | -₩3.7B | -₩10.1B | −3.5% | −5.0% | 51.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14
On a disclosed basis, revenue went from KRW 82.2 billion in 2022 to KRW 93.9 billion in 2023 (up 14.2%), KRW 99.1 billion in 2024 (up 5.5%) and KRW 105.2 billion in 2025 (up 6.2%), rising for three consecutive years from 2023 through 2025, with 2025 the largest year of the 2022 to 2025 period.
Press reports described crossing KRW 100 billion in annual sales as a first for the company. Operating profit fell from KRW 2.98 billion in 2022 and KRW 3.04 billion in 2023 to KRW 1.02 billion in 2024 (down 66.4%), and the company posted an operating loss of KRW 3.69 billion in 2025.
The operating margin slid from 3.6% in 2022 to 3.2% in 2023 and 1.0% in 2024, reaching -3.5% in 2025.
The company attributed the 2025 deterioration mainly to higher selling and administrative expenses after a change in its sales structure, and to higher non-operating expenses from fair-value measurement, which lowered net profit.
Reports put 2025 selling and administrative expenses at KRW 64.6 billion, roughly KRW 20 billion higher than the year before, and R&D spending at around KRW 10 billion a year.
Controlling-shareholder net profit swung to profit of KRW 6.46 billion in 2023 and then fell to KRW 2.69 billion in 2024 (down 58.3%) before turning into a loss of KRW 10.1 billion in 2025.
In the first quarter of 2026 revenue was KRW 25.5 billion (down 19.1% from the prior quarter) with an operating loss of KRW 2.92 billion; the second quarter brought revenue of KRW 28.3 billion and an operating loss of KRW 2.95 billion; the third quarter brought revenue of KRW 22.8 billion (down 25.1% year on year) and an operating loss of KRW 4.96 billion.
Controlling-shareholder net profit was positive in the first two quarters of 2026, but the third quarter swung to a net loss of KRW 13 billion, and the cumulative controlling-shareholder net loss for the last four quarters totals KRW 14 billion.
Operating cash flow fell from KRW 5.14 billion in 2022 to KRW 290 million in 2024 and to -KRW 11 billion in 2025.
In the schizophrenia and CNS segment where the company competes, reports note that the aripiprazole indication has grown more than 15% a year. A competitor's similar film-type schizophrenia product received FDA approval first, which is seen as a disadvantage in establishing market position.
In a 2024 interview, the company said it expected a 3% to 5% share of the US psychiatric drug market and annual sales of KRW 60 billion to KRW 100 billion.
In the domestic oral anticoagulant market, Lixiana recorded about KRW 121.8 billion in outpatient prescription sales last year, which indicates the size of the generic opportunity. The edoxaban generic's reimbursement price is about 36% below the original's price after its cut.
Hanmi Pharm also launched an anticoagulant around the same period, which suggests competition in this generic segment could intensify. The company says it uses registered drug master files and handles manufacturing and quality control at its own plant.
Industry observers see the commercial track record and the share of overseas revenue as the key variables for re-rating. Beyond psychiatric drugs, the company is reviewing broader indications for its ODF platform. Compared with large listed pharma companies, its business remains weighted toward generics.
The company plans to launch more than 20 new products by 2030, including differentiated generics. Mezofy is in coordination with production and distribution partners to enter the local market after its April 2025 FDA approval.
A report on the first-quarter results said the planned launch within the second quarter had not yet taken place. The company's target is annual sales above KRW 100 billion within five years of entering the US market. In ETC, it is preparing launches including a lipid-lowering drug and a tablet enzyme product.
The combination improved drug CMG1903 is in a Korean Phase 3 trial and multinational trials for overseas entry, and a diabetes-hypertension combination CMG1904 is also being pursued.
Among its new drugs, the lung cancer candidate is in the selection stage for a next-generation compound aimed at overcoming acquired resistance. The company set a 2030 sales goal of KRW 500 billion in a 2024 interview.
After the reverse split, the company said it aims to improve medium-term earnings through R&D, new product launches, external partnerships and upgraded production facilities.
The next checkpoints are whether Mezofy starts US sales, how much the edoxaban generic contributes to quarterly results, and how far the operating margin recovers from losses.
Because the company has posted controlling-shareholder net losses over the last four quarters, its price-to-earnings ratio cannot be calculated. The price-to-book ratio is below 1x, so the stock trades at a discount to net asset value.
Total equity at the end of 2025 was KRW 201.6 billion, all attributable to controlling shareholders, against total liabilities of KRW 104.4 billion. The debt ratio rose from 15.3% in 2022 to 60.1% in 2024 before easing to 51.8% in 2025.
The dividend yield is effectively zero, so the investment case does not rely on cash returns. Analysts once described the multiple as near the bottom of a five-year valuation band, but that was during a period of profit.
Because the reverse split changed per-share levels, direct comparisons with older per-share figures need care. How the multiple reads will depend on whether the company returns to profit and recovers operating income.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14
Revenue rose for three straight years through 2025 to KRW 105.2 billion. The bull case is that a larger revenue base could widen margins if profitability recovers. The operating margin, however, fell to -3.5% in 2025.
Mezofy received FDA marketing approval in April 2025, clearing the regulatory hurdle for US entry. The company targets annual sales above KRW 100 billion within five years of US market entry. The absence of a competing film-type schizophrenia product is cited as support for market potential.
Launches including the edoxaban generic in November 2026 are broadening the cardiovascular portfolio alongside improved drugs. The company plans more than 20 new products by 2030, including differentiated generics. Lixiana's outpatient prescription sales of about KRW 121.8 billion are cited as room for generic expansion.
Operating losses have continued from the first quarter through the third quarter of 2026, with the third-quarter loss widening to KRW 4.96 billion. Cumulative controlling-shareholder net losses over the last four quarters total KRW 14 billion. Operating cash flow also deteriorated to -KRW 11 billion in 2025, leaving cash generation as an open issue.
Reports say selling and administrative expenses rose to KRW 64.6 billion in 2025, roughly KRW 20 billion higher. Annual R&D spending of around KRW 10 billion weighs on near-term profit as investment in new and improved drugs continues.
Industry observers note that the CNS and improved-drug businesses have not yet become a meaningful profit contributor.
After a share-price decline the stock was flagged as a candidate for administrative-issue designation, and the company pursued a 10-for-1 reverse split. Trading resumed on October 27, 2026 after the relisting tied to the par-value consolidation.
The company itself said the split alone is not enough and that competitiveness and profitability must be strengthened.
Even after FDA approval, Mezofy's US prescription uptake, distribution reach and revenue contribution require further verification. The approval process was delayed after the original 2019 filing. The missed second-quarter launch target could push back the timing of revenue.
The company plans to invest a total of KRW 170 billion in plant renovation, a second factory and CDMO capacity, including convertible bond proceeds. A past convertible bond issue includes a call option that opens the possibility of a larger stake for the largest shareholder. With operating losses continuing, the effect of capital spending on the balance sheet needs monitoring.
The edoxaban generic launched at a reimbursement price about 36% below the original, which means lower revenue per tablet. Other pharma companies are also launching anticoagulant generics.
As with a competing film-type schizophrenia product that won FDA approval first, the timing of rival entry is a variable for Mezofy.
The 2026 annual report deadline, when full-year operating profit and controlling-shareholder net income are finalized. The key checks are whether the 2026 operating losses carried through the full year and how much the edoxaban generic contributed.
The deadline for the first-quarter 2027 report. The checks are whether the operating loss narrows after three straight loss quarters and whether selling expenses stabilize.
Whether talks with production and distribution partners conclude and a US launch of Mezofy is announced. Post-launch prescriptions and revenue will be the benchmark for commercial results.
Results from the Korean Phase 3 trial and multinational trials of CMG1903. Clinical outcomes will underpin overseas entry and medium-term revenue plans.
Revenue rose for three straight years through 2025 to KRW 105.2 billion, while the operating margin fell from 3.6% to -3.5% over the same period.
After an operating loss of KRW 3.69 billion and a controlling-shareholder net loss of KRW 10.1 billion in 2025, operating losses continued for three consecutive quarters from the first quarter through the third quarter of 2026.
The bull side points to Mezofy's FDA approval in April 2025 and the November 2026 edoxaban generic launch as evidence of portfolio expansion. The bear side points to unverified US prescription uptake and the burden of selling and R&D costs.
Total equity of KRW 201.6 billion and a debt ratio of 51.8% provide a cushion, but operating cash flow of -KRW 11 billion keeps funding capacity in focus. Trading resumed on October 27, 2026 after the relisting that followed the reverse split.
The next checkpoints are the operating margin in the 2026 annual report, the first-quarter 2027 report, and whether Mezofy begins US sales.
Report written 2026-11-14 · Data as of 2026-11-13
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.